Advanced search
Publication Cover
mAbs Volume 5, 2013 - Issue 1
Submit an article Journal homepage
7,030
Views
189
CrossRef citations to date
0
Altmetric
Review

Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates

Michael Ritchie Global Biotherapeutic Technologies; Pfizer Global Research and Development; Cambridge, MA USA
,
Lioudmila Tchistiakova Global Biotherapeutic Technologies; Pfizer Global Research and Development; Cambridge, MA USA
&
Nathan Scott Global Biotherapeutic Technologies; Pfizer Global Research and Development; Cambridge, MA USACorrespondence[email protected]
Pages 13-21 | Published online: 06 Dec 2012

Citations (189)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (10)

Rebecca L. Porter & Ursula A. Matulonis. (2023) Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer. Expert Review of Anticancer Therapy 23:8, pages 783-796.
Read now
Martin De Cecco, Daniel N. Galbraith & Lisa L. McDermott. (2021) What makes a good antibody–drug conjugate?. Expert Opinion on Biological Therapy 21:7, pages 841-847.
Read now
Corinne A. Calo & David M. O’Malley. (2021) Antibody-drug conjugates for the treatment of ovarian cancer. Expert Opinion on Biological Therapy 21:7, pages 875-887.
Read now
Paul Malik & Andrea Edginton. (2018) Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opinion on Drug Metabolism & Toxicology 14:6, pages 585-599.
Read now
Ricarda M. Hoffmann, Ben G. T. Coumbe, Debra H. Josephs, Silvia Mele, Kristina M. Ilieva, Anthony Cheung, Andrew N. Tutt, James F. Spicer, David E. Thurston, Silvia Crescioli & Sophia N. Karagiannis. (2018) Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). OncoImmunology 7:3.
Read now
Shaoyi Chen, Stelios Florinas, Abigail Teitgen, Ze-Qi Xu, Changshou Gao, Herren Wu, Kazunori Kataoka, Horacio Cabral & R. James Christie. (2017) Controlled Fab installation onto polymeric micelle nanoparticles for tuned bioactivity. Science and Technology of Advanced Materials 18:1, pages 666-680.
Read now
Muhammad Kalim, Jie Chen, Shenghao Wang, Caiyao Lin, Saif Ullah, Keying Liang, Qian Ding, Shuqing Chen & Jinbiao Zhan. (2017) Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates. Drug Design, Development and Therapy 11, pages 2265-2276.
Read now
Devin B. Lowe, Camille K. Bivens, Alexis S. Mobley, Christian E. Herrera, Amanda L. McCormick, Timea Wichner, Manoj K. Sabnani, Laurence M. Wood & Jon A. Weidanz. (2017) TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets. mAbs 9:4, pages 603-614.
Read now
Dong-Ki Choi, Jeomil Bae, Seung-Min Shin, Ju-Yeon Shin, Sunghoon Kim & Yong-Sung Kim. (2014) A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells. mAbs 6:6, pages 1402-1414.
Read now
Siler Panowski, Sunil Bhakta, Helga Raab, Paul Polakis & Jagath R Junutula. (2014) Site-specific antibody drug conjugates for cancer therapy. mAbs 6:1, pages 34-45.
Read now

Articles from other publishers (179)

Weiliang Zhuang, Wei Zhang, Lei Wang, Liping Xie, Jun Feng, Baohong Zhang & Youjia Hu. (2023) Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor. International Journal of Molecular Sciences 24:22, pages 16056.
Crossref
Chi Hun Song, Minchan Jeong, Hyukmin In, Ji Hoe Kim, Chih-Wei Lin & Kyung Ho Han. (2023) Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy. Antibodies 12:4, pages 72.
Crossref
Ritchu Babbar, Vanya, Aarti Bassi, Rashmi Arora, Ankur Aggarwal, Pranay Wal, Sunil Kumar Dwivedi, Salma Alolayan, Monica Gulati, Celia Vargas-De-La-Cruz, Tapan Behl & Shreesh Ojha. (2023) Understanding the promising role of antibody drug conjugates in breast and ovarian cancer. Heliyon 9:11, pages e21425.
Crossref
F. Mosele, G. Montagnac, B. Pistilli & F. André. (2023) Optimizing the potential of antibody–drug conjugates in oncology. Annals of Oncology 34:11, pages 964-967.
Crossref
Green Ahn, Nicholas M. Riley, Roarke A. Kamber, Simon WisnovskySalvador Moncayo von Hase, Michael C. Bassik, Steven M. Banik & Carolyn R. Bertozzi. (2023) Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras. Science 382:6668.
Crossref
Emenike Kenechi Onyido, David James, Jezabel Garcia-Parra, John Sinfield, Anna Moberg, Zoe Coombes, Jenny Worthington, Nicole Williams, Lewis Webb Francis, Robert Steven Conlan & Deyarina Gonzalez. (2023) Elucidating Novel Targets for Ovarian Cancer Antibody–Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity. Antibodies 12:4, pages 65.
Crossref
Sandra Kannampuzha, Reshma Murali, Abilash Valsala Gopalakrishnan, Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Arunraj Namachivayam, Alex George, Abhijit Dey & Balachandar Vellingiri. (2023) Novel biomolecules in targeted cancer therapy: a new approach towards precision medicine. Medical Oncology 40:11.
Crossref
Ilana Schlam, Ruth Moges, Stefania Morganti, Sara M. Tolaney & Paolo Tarantino. (2023) Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2. Critical Reviews in Oncology/Hematology 190, pages 104090.
Crossref
Natalia Porębska, Krzysztof Ciura, Aleksandra Chorążewska, Małgorzata Zakrzewska, Jacek Otlewski & Łukasz Opaliński. (2023) Multivalent protein-drug conjugates – An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells. Biotechnology Advances 67, pages 108213.
Crossref
Pooja Gogia, Hamza Ashraf, Sidharth Bhasin & Yiqing Xu. (2023) Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence. Cancers 15:15, pages 3886.
Crossref
Joshua Hurwitz, Lucy Roxana Haggstrom & Elgene Lim. (2023) Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy. Pharmaceutics 15:8, pages 2017.
Crossref
Feng Yin, Farah Ahsan, Jan Pinkas, Biplab Das, Frank Wang, Nancy Zheng, David Hahn, Aniruddha Amrite, Jianwen Feng, Diana Adhikari, Jack Sikora, Elizabeth Shaheen & Shawn Harriman. (2023) A sensitive LC–MS/MS assay to quantitate free payload Aur0101 from ADC PYX-201 in rat and monkey plasma. Bioanalysis 15:14, pages 833-843.
Crossref
Blerida Banushi, Shannon R. Joseph, Benedict Lum, Jason J. Lee & Fiona Simpson. (2023) Endocytosis in cancer and cancer therapy. Nature Reviews Cancer 23:7, pages 450-473.
Crossref
Alissa J. Cooper & Rebecca S. Heist. (2023) New Therapies on the Horizon. Hematology/Oncology Clinics of North America 37:3, pages 623-658.
Crossref
Peyton High & Kendra S. Carmon. (2023) G protein-coupled receptor-targeting antibody-drug conjugates: Current status and future directions. Cancer Letters 564, pages 216191.
Crossref
Farah Raheem & Vishal Shah. 2023. Breast Cancer Updates. Breast Cancer Updates.
Hannah C. Karpel, Sachia Stonefeld Powell & Bhavana Pothuri. (2023) Antibody-Drug Conjugates in Gynecologic Cancer. American Society of Clinical Oncology Educational Book:43.
Crossref
Lijie Xing, Yuntong Liu & Jiye Liu. (2023) Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy. Cancers 15:8, pages 2240.
Crossref
Hao Wu, Xuefeng Ding, Yun Chen, Yanfei Cai, Zhaoqi Yang & Jian Jin. (2023) Constructed Tumor-Targeted and MMP-2 Biocleavable Antibody Conjugated Silica Nanoparticles for Efficient Cancer Therapy. ACS Omega 8:14, pages 12752-12760.
Crossref
Dipankar Pramanik. (2023) Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment. Anti-Cancer Agents in Medicinal Chemistry 23:6, pages 642-657.
Crossref
Benjamina Esapa, Jiexuan Jiang, Anthony Cheung, Alicia Chenoweth, David E. Thurston & Sophia N. Karagiannis. (2023) Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. Cancers 15:6, pages 1845.
Crossref
Andres E. Perez Bay, Devon Faulkner, John O. DaSilva, Tara M. Young, Katie Yang, Jason T. Giurleo, Dangshe Ma, Frank J. Delfino, William C. Olson, Gavin Thurston, Christopher Daly & Julian Andreev. (2023) A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes. Molecular Cancer Therapeutics 22:3, pages 357-370.
Crossref
Yu‐Fei Chen, Ying‐ying Xu, Zhi‐Ming Shao & Ke‐Da Yu. (2022) Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions. Cancer Communications 43:3, pages 297-337.
Crossref
Abhilash Rana, Meheli Adhikary, Praveen Kumar Singh, Bhudev C. Das & Seema Bhatnagar. (2023) “Smart” drug delivery: A window to future of translational medicine. Frontiers in Chemistry 10.
Crossref
Jiansheng Fan & Shuqing Chen. 2023. Antibody-Drug Conjugates and Cellular Metabolic Dynamics. Antibody-Drug Conjugates and Cellular Metabolic Dynamics 25 34 .
Günter Niegisch. 2023. Urothelial Carcinoma. Urothelial Carcinoma 293 301 .
An-Jin Wang, Yang Gao, Yu-Ying Shi, Meng-Yuan Dai & Hong-Bing Cai. (2022) A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer. Frontiers in Pharmacology 13.
Crossref
Monika Biasizzo, Urban Javoršek, Eva Vidak, Miki Zarić & Boris Turk. (2022) Cysteine cathepsins: A long and winding road towards clinics. Molecular Aspects of Medicine 88, pages 101150.
Crossref
Mythili Shastry, Saya Jacob, Hope S. Rugo & Erika Hamilton. (2022) Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. The Breast 66, pages 169-177.
Crossref
Jingjing Yang, Anthony Griffin, Zhe Qiang & Jie Ren. (2022) Organelle-targeted therapies: a comprehensive review on system design for enabling precision oncology. Signal Transduction and Targeted Therapy 7:1.
Crossref
Jayastu Senapati, Naval G. Daver & Naveen Pemmaraju. (2022) Antibody-Drug Conjugates in Myeloid Leukemias. The Cancer Journal 28:6, pages 454-461.
Crossref
Xun Qin, Zhen Ni, Jianjun Jiang, Xiguang Liu, Xiaoying Dong, Mei Li, Kai Miao, Shuan Rao, Wenqing Zhang & Kaican Cai. (2022) High‐throughput membrane‐anchored proteome screening reveals PIEZO1 as a promising antibody‐drug target for human esophageal squamous cell carcinoma . Cancer Medicine 11:19, pages 3700-3713.
Crossref
Zaria Malindi, Stefan Barth & Heidi Abrahamse. (2022) The Potential of Antibody Technology and Silver Nanoparticles for Enhancing Photodynamic Therapy for Melanoma. Biomedicines 10:9, pages 2158.
Crossref
Emily R. Webb, Julia Moreno-Vicente, Alistair Easton, Silvia Lanati, Martin Taylor, Sonya James, Emily L. Williams, Vikki English, Chris Penfold, Stephen A. Beers & Juliet C. Gray. (2022) Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma. iScience 25:9, pages 104995.
Crossref
Hany E. Marei, Carlo Cenciarelli & Anwarul Hasan. (2022) Potential of antibody–drug conjugates (ADCs) for cancer therapy. Cancer Cell International 22:1.
Crossref
Marta Poźniak, Dominika Żukowska, Aleksandra Gędaj, Mateusz Adam Krzyścik, Natalia Porębska, Małgorzata Zakrzewska, Jacek Otlewski & Łukasz Opaliński. (2022) The Significance of Cell Surface N-Glycosylation for Internalization and Potency of Cytotoxic Conjugates Targeting Receptor Tyrosine Kinases. International Journal of Molecular Sciences 23:15, pages 8514.
Crossref
Iván Cheng-Sánchez, Federico Moya-Utrera, Cristina Porras-Alcalá, Juan M. López-Romero & Francisco Sarabia. (2022) Antibody-Drug Conjugates Containing Payloads from Marine Origin. Marine Drugs 20:8, pages 494.
Crossref
Babette Wolf, Mateusz Piksa, Isabelle Beley, Agnes Patoux, Thierry Besson, Valerie Cordier, Bernd Voedisch, Patrick Schindler, Daniela Stöllner, Ludovic Perrot, Stephan von Gunten, Dominique Brees & Michael Kammüller. (2022) Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity. Immunology 166:3, pages 380-407.
Crossref
Lavinia Dunsmore, Claudio D. Navo, Julie Becher, Enrique Gil de Montes, Ana Guerreiro, Emily Hoyt, Libby Brown, Viviane Zelenay, Sigitas Mikutis, Jonathan Cooper, Isaia Barbieri, Stefanie Lawrinowitz, Elise Siouve, Esther Martin, Pedro R. Ruivo, Tiago Rodrigues, Filipa P. da Cruz, Oliver Werz, George Vassiliou, Peter Ravn, Gonzalo Jiménez-Osés & Gonçalo J. L. Bernardes. (2022) Controlled masking and targeted release of redox-cycling ortho-quinones via a C–C bond-cleaving 1,6-elimination. Nature Chemistry 14:7, pages 754-765.
Crossref
Jong Hyuk Byun, In-Soo Yoon, Song Yi Lee, Hyun-Jong Cho & Il Hyo Jung. (2022) Extended transit compartment model to describe tumor delay using Coxian distribution. Scientific Reports 12:1.
Crossref
Dawid Sigorski, Paweł Różanowski, Ewa Iżycka-Świeszewska & Katarzyna Wiktorska. (2022) Antibody–Drug Conjugates in Uro-Oncology. Targeted Oncology 17:3, pages 203-221.
Crossref
Siddharth Menon, Sagun Parakh, Andrew M. Scott & Hui K. Gan. (2022) Antibody-drug conjugates: beyond current approvals and potential future strategies. Exploration of Targeted Anti-tumor Therapy, pages 252-277.
Crossref
Marta Nerone, Maria Del Grande, Cristiana Sessa & Ilaria Colombo. (2022) Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?. Exploration of Targeted Anti-tumor Therapy, pages 149-171.
Crossref
Zhiwen Fu, Shijun Li, Sifei Han, Chen Shi & Yu Zhang. (2022) Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduction and Targeted Therapy 7:1.
Crossref
Khushboo Singh, Mine Canakci, Pintu Kanjilal, Natalie Williams, Sudarvili Shanthalingam, Barbara A. Osborne & S. Thayumanavan. (2022) Evaluation of Cellular Targeting by Fab′ vs Full-Length Antibodies in Antibody–Nanoparticle Conjugates (ANCs) Using CD4 T-cells. Bioconjugate Chemistry 33:3, pages 486-495.
Crossref
Tanmoy Mondal, Gururaj Shivange, Alaa Habieb & Jogender Tushir-Singh. (2022) A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle. Microbiology Spectrum 10:1.
Crossref
Chris Kedong Wang, Irina Nelepcu, Desmond Hui, Htoo Zarni Oo, Sarah Truong, Sarah Zhao, Zakir Tahiry, Shaghayegh Esfandnia, Fariba Ghaidi, Hans Adomat, Robert Dagil, Tobias Gustavsson, Swati Choudhary, Ali Salanti, Poul H. Sorensen, Nader Al Nakouzi & Mads Daugaard. (2022) Internalization and trafficking of CSPG-bound recombinant VAR2CSA lectins in cancer cells. Scientific Reports 12:1.
Crossref
Yiming Jin, Megan A. Schladetsch, Xueting Huang, Marcy J. Balunas & Andrew J. Wiemer. (2022) Stepping forward in antibody-drug conjugate development. Pharmacology & Therapeutics 229, pages 107917.
Crossref
Sami El Khatib & Mohamed Salla. (2022) The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics. Leukemia Research Reports 18, pages 100335.
Crossref
Elena Díaz-Rodríguez, Lucía Gandullo-Sánchez, Alberto Ocaña & Atanasio Pandiella. (2021) Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers 14:1, pages 154.
Crossref
M. Frigerio & N. Camper. 2021. Chemical Linkers in Antibody–Drug Conjugates (ADCs). Chemical Linkers in Antibody–Drug Conjugates (ADCs) 71 135 .
Olav Engebraaten, Christina Yau, Kristian Berg, Elin Borgen, Øystein Garred, Maria E. B. Berstad, Ane S. V. Fremstedal, Angela DeMichele, Laura van ’t Veer, Laura Esserman & Anette Weyergang. (2021) RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer. Nature Communications 12:1.
Crossref
Vishnu Raman, Nele Van Dessel, Christopher L. Hall, Victoria E. Wetherby, Samantha A. Whitney, Emily L. Kolewe, Shoshana M. K. Bloom, Abhinav Sharma, Jeanne A. Hardy, Mathieu Bollen, Aleyde Van Eynde & Neil S. Forbes. (2021) Intracellular delivery of protein drugs with an autonomously lysing bacterial system reduces tumor growth and metastases. Nature Communications 12:1.
Crossref
Marta Poblocka, Akang Leonard Bassey, Victoria M. Smith, Marta Falcicchio, Ana Sousa Manso, Mohammad Althubiti, XiaoBo Sheng, Andrew Kyle, Ruth Barber, Mark Frigerio & Salvador Macip. (2021) Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker. Scientific Reports 11:1.
Crossref
Juliana T. W. Tong, Paul W. R. Harris, Margaret A. Brimble & Iman Kavianinia. (2021) An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules 26:19, pages 5847.
Crossref
Alireza Shoari, Raheleh Tooyserkani, Mehdi Tahmasebi & Dennis W. P. M. Löwik. (2021) Delivery of Various Cargos into Cancer Cells and Tissues via Cell-Penetrating Peptides: A Review of the Last Decade. Pharmaceutics 13:9, pages 1391.
Crossref
Charles Shin, Sung Soo Kim & Yong Hwa Jo. (2021) Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications. Molecular Therapy - Oncolytics 22, pages 166-179.
Crossref
Jian-Ming Lü, Zhengdong Liang, Dongliang Liu, Bin Zhan, Qizhi Yao & Changyi Chen. (2021) Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids. Pharmaceuticals 14:9, pages 841.
Crossref
David M. O’Malley & Corinne A. Calo. (2021) Progress in Gynecologic Cancers with Antibody Drug Conjugates. Current Oncology Reports 23:8.
Crossref
Desh Deepak Singh & Dharmendra Kumar Yadav. (2021) TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy. Biomedicines 9:8, pages 876.
Crossref
Manar Hammood, Andrew Craig & Jeffrey Leyton. (2021) Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development. Pharmaceuticals 14:7, pages 674.
Crossref
Elias Jabbour, Shilpa Paul & Hagop Kantarjian. (2021) The clinical development of antibody–drug conjugates — lessons from leukaemia. Nature Reviews Clinical Oncology 18:7, pages 418-433.
Crossref
Joshua Z. Drago, Shanu Modi & Sarat Chandarlapaty. (2021) Unlocking the potential of antibody–drug conjugates for cancer therapy. Nature Reviews Clinical Oncology 18:6, pages 327-344.
Crossref
Jan P. Bogen, Julius Grzeschik, Joern Jakobsen, Alexandra Bähre, Björn Hock & Harald Kolmar. (2021) Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics. Frontiers in Oncology 11.
Crossref
Vesela Kostova, Patrice Désos, Jérôme-Benoît Starck & Andras Kotschy. (2021) The Chemistry Behind ADCs. Pharmaceuticals 14:5, pages 442.
Crossref
Betül Altunay, Agnieszka Morgenroth, Mohsen Beheshti, Andreas Vogg, Nicholas C. L. Wong, Hong Hoi Ting, Hans-Jürgen Biersack, Elmar Stickeler & Felix M. Mottaghy. (2020) HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. European Journal of Nuclear Medicine and Molecular Imaging 48:5, pages 1371-1389.
Crossref
Canyu Yang, Bing He, Wenbing Dai, Hua Zhang, Ying Zheng, Xueqing Wang & Qiang Zhang. (2021) The role of caveolin-1 in the biofate and efficacy of anti-tumor drugs and their nano-drug delivery systems. Acta Pharmaceutica Sinica B 11:4, pages 961-977.
Crossref
Trevor S. Anderson, Amanda L. Wooster, Ninh M. La-Beck, Dipongkor Saha & Devin B. Lowe. (2020) Antibody-drug conjugates: an evolving approach for melanoma treatment. Melanoma Research 31:1, pages 1-17.
Crossref
Liwei Jiang, Sungwook Jung, Jing Zhao, Vivek Kasinath, Takaharu Ichimura, John Joseph, Paolo Fiorina, Andrew S. Liss, Khalid Shah, Nasim Annabi, Nitin Joshi, Tomoya O. Akama, Jonathan S. Bromberg, Motohiro Kobayashi, Kenji Uchimura & Reza Abdi. (2021) Simultaneous targeting of primary tumor, draining lymph node, and distant metastases through high endothelial venule-targeted delivery. Nano Today 36, pages 101045.
Crossref
Jorge Marquez, Jianping Dong, Chun Dong, Changsheng Tian & Ginette Serrero. (2021) Identification of Prostaglandin F2 Receptor Negative Regulator (PTGFRN) as an internalizable target in cancer cells for antibody-drug conjugate development. PLOS ONE 16:1, pages e0246197.
Crossref
Sophia N. Karagiannis, Ricarda M. Hoffmann, Mano Nakamura, Silvia Crescioli, Heather J. Bax, Alicia Chenoweth, Anthony Cheung, Sophia Tsoka, James F. Spicer, Katie E. Lacy & David E. Thurston. 2021. Principles of Translational Science in Medicine. Principles of Translational Science in Medicine 329 350 .
Juan Manuel Domínguez, Gema Pérez-Chacón, María José Guillén, María José Muñoz-Alonso, Beatriz Somovilla-Crespo, Danay Cibrián, Bárbara Acosta-Iborra, Magdalena Adrados, Cecilia Muñoz-Calleja, Carmen Cuevas, Francisco Sánchez-Madrid, Pablo Avilés & Juan M. Zapata. (2020) CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110. Journal of Hematology & Oncology 13:1.
Crossref
Jessica C. Graham, Jedd Hillegass & Gene Schulze. (2020) Considerations for setting occupational exposure limits for novel pharmaceutical modalities. Regulatory Toxicology and Pharmacology 118, pages 104813.
Crossref
Umbreen Hafeez, Sagun Parakh, Hui K. Gan & Andrew M. Scott. (2020) Antibody–Drug Conjugates for Cancer Therapy. Molecules 25:20, pages 4764.
Crossref
Jackie Cheng, Meina Liang, Miguel F. Carvalho, Natalie Tigue, Raffaella Faggioni, Lorin K. Roskos & Inna Vainshtein. (2020) Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody. Antibodies 9:3, pages 49.
Crossref
Peiying Zuo. (2020) Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates. The AAPS Journal 22:5.
Crossref
Aranzazu Manzano & Alberto Ocaña. (2020) Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. Cancers 12:8, pages 2223.
Crossref
Yuan‐Chiang Chung, Hsi‐Hsiung Chiu, Wan‐Chen Wei, King‐Jen Chang & Wei‐Ting Chao. (2020) Application of trastuzumab emtansine in HER‐2–positive and KRAS/BRAF‐mutated colon cancer cells. European Journal of Clinical Investigation 50:8.
Crossref
Nai-Shu Hsu, Cheng-Chung Lee, Wen-Chih Kuo, Ya-Wen Chang, Shin-Yi Lo & Andrew H.-J. Wang. (2020) Development of a Versatile and Modular Linker for Antibody–Drug Conjugates Based on Oligonucleotide Strand Pairing. Bioconjugate Chemistry 31:7, pages 1804-1811.
Crossref
Mateusz Adam Krzyscik, Małgorzata Zakrzewska & Jacek Otlewski. (2020) Site-Specific, Stoichiometric-Controlled, PEGylated Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1 (FGFR1). Molecular Pharmaceutics 17:7, pages 2734-2748.
Crossref
I-Ju Chen, Yi-An Cheng, Kai-Wen Ho, Wen-Wei Lin, Kai-Wen Cheng, Yun-Chi Lu, Yuan-Chin Hsieh, Chien-Chiao Huang, Chih-Hung Chuang, Fang-Ming Chen, Yu-Cheng Su, Steve R. Roffler & Tian-Lu Cheng. (2020) Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes. Acta Biomaterialia 111, pages 386-397.
Crossref
Eunhee G. Kim, Jieun Jeong, Junghyeon Lee, Hyeryeon Jung, Minho Kim, Yi Zhao, Eugene C. Yi & Kristine M. Kim. (2020) Rapid Evaluation of Antibody Fragment Endocytosis for Antibody Fragment–Drug Conjugates. Biomolecules 10:6, pages 955.
Crossref
Jie Liu, Seethu Xavy, Shirley Mihardja, Sharline Chen, Kavitha Sompalli, Dongdong Feng, Timothy Choi, Balaji Agoram, Ravindra Majeti, Irving L. Weissman & Jens-Peter Volkmer. (2020) Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy. JCI Insight 5:12.
Crossref
Kohsuke Gonda, Hiroshi Negishi, Mayumi Takano-Kasuya, Narufumi Kitamura, Naoko Furusawa, Yasushi Nakano, Yoh Hamada, Masayuki Tokunaga, Hideo Higuchi, Hiroshi Tada & Takanori Ishida. (2020) Heterogeneous Drug Efficacy of an Antibody-Drug Conjugate Visualized Using Simultaneous Imaging of Its Delivery and Intracellular Damage in Living Tumor Tissues. Translational Oncology 13:6, pages 100764.
Crossref
Ying Han, Yifan Da, Mingjia Yu, Yaping Cheng, Xin Wang, Jiale Xiong, Guoying Guo, Yan Li, Xianxing Jiang & Xiaoqing Cai. (2020) Protein labeling approach to improve lysosomal targeting and efficacy of antibody–drug conjugates. Organic & Biomolecular Chemistry 18:17, pages 3229-3233.
Crossref
Sara García-Alonso, Alberto Ocaña & Atanasio Pandiella. (2020) Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. Trends in Cancer 6:2, pages 130-146.
Crossref
Nooshafarin Amani, Farid Abedin Dorkoosh & Hamid Mobedi. (2020) ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies. Current Drug Delivery 17:1, pages 23-51.
Crossref
Puregmaa Khongorzul, Cai Jia Ling, Farhan Ullah Khan, Awais Ullah Ihsan & Juan Zhang. (2020) Antibody–Drug Conjugates: A Comprehensive Review. Molecular Cancer Research 18:1, pages 3-19.
Crossref
Suzana Aulic, Domenico Marson, Erik Laurini, Maurizio Fermeglia & Sabrina Pricl. 2020. Nanomedicines for Breast Cancer Theranostics. Nanomedicines for Breast Cancer Theranostics 371 404 .
Sagun Parakh, Dylan King, Hui K. Gan & Andrew M. Scott. 2020. Current Immunotherapeutic Strategies in Cancer. Current Immunotherapeutic Strategies in Cancer 1 70 .
Julie Gaston, Nicolas Maestrali, Guilhem Lalle, Marie Gagnaire, Alessandro Masiero, Bruno Dumas, Tarik Dabdoubi, Katarina Radošević & Pierre-François Berne. (2019) Intracellular delivery of therapeutic antibodies into specific cells using antibody-peptide fusions. Scientific Reports 9:1.
Crossref
Mark L. Chiu, Dennis R. Goulet, Alexey Teplyakov & Gary L. Gilliland. (2019) Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies 8:4, pages 55.
Crossref
Zhengqiu Zhou, Grant L. Austin, Robert Shaffer, Dustin D. Armstrong & Matthew S. Gentry. (2019) Antibody-Mediated Enzyme Therapeutics and Applications in Glycogen Storage Diseases. Trends in Molecular Medicine 25:12, pages 1094-1109.
Crossref
Girgis Obaid, Shazia Bano, Srivalleesha Mallidi, Mans Broekgaarden, Jerrin Kuriakose, Zachary Silber, Anne-Laure Bulin, Yucheng Wang, Zhiming Mai, Wendong Jin, Diane Simeone & Tayyaba Hasan. (2019) Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors with Specificity-Tuned, NIR-Activable Photoimmunonanoconjugates: Towards Conquering Desmoplasia? . Nano Letters 19:11, pages 7573-7587.
Crossref
C. Kimberly Tsui, Robyn M. Barfield, Curt R. Fischer, David W. Morgens, Amy Li, Benjamin A. H. Smith, Melissa Anne Gray, Carolyn R. Bertozzi, David Rabuka & Michael C. Bassik. (2019) CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity. Nature Chemical Biology 15:10, pages 949-958.
Crossref
Fatemeh Yarian, Abbas Alibakhshi, Shirin Eyvazi, Roghaye Arezumand & Shahrzad Ahangarzadeh. (2019) Antibody‐drug therapeutic conjugates: Potential of antibody‐siRNAs in cancer therapy. Journal of Cellular Physiology 234:10, pages 16724-16738.
Crossref
Jiayu Liu, Xiaoqiong Wu, Limin Lin, Haitao Pan, Yanlan Wang, Yumei Li, Yining Zhao & Zhong Wang. (2019) Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities. Molecular Therapy - Oncolytics 14, pages 66-73.
Crossref
Cindy H Chau, Patricia S Steeg & William D Figg. (2019) Antibody–drug conjugates for cancer. The Lancet 394:10200, pages 793-804.
Crossref
Meghdad Abdollahpour‐Alitappeh, Majid Lotfinia, Tohid Gharibi, Jalal Mardaneh, Behrouz Farhadihosseinabadi, Pegah Larki, Babak Faghfourian, Koushan Sineh Sepehr, Kazem Abbaszadeh‐Goudarzi, Ghasem Abbaszadeh‐Goudarzi, Behrooz Johari, Mohammad Reza Zali & Nader Bagheri. (2018) Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. Journal of Cellular Physiology 234:5, pages 5628-5642.
Crossref
Jordon Sandland & Ross W. Boyle. (2019) Photosensitizer Antibody–Drug Conjugates: Past, Present, and Future. Bioconjugate Chemistry 30:4, pages 975-993.
Crossref
Emily C. Cox, Dana N. Thornlow, Michaela A. Jones, Jordan L. Fuller, Judith H. Merritt, Matthew J. Paszek, Christopher A. Alabi & Matthew P. DeLisa. (2019) Antibody-Mediated Endocytosis of Polysialic Acid Enables Intracellular Delivery and Cytotoxicity of a Glycan-Directed Antibody–Drug Conjugate. Cancer Research 79:8, pages 1810-1821.
Crossref
Hongjiao Xu, Lu Gan, Ying Han, Yifan Da, Jiale Xiong, Sihua Hong, Qian Zhao, Nazi Song, Xiaoqing Cai & Xianxing Jiang. (2019) Site-specific labeling of an anti-MUC1 antibody: probing the effects of conjugation and linker chemistry on the internalization process. RSC Advances 9:4, pages 1909-1917.
Crossref
Gareth D. Healey, Asa Frostell, Tim Fagge, Deyarina Gonzalez & R. Steven Conlan. (2019) A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development. Antibodies 8:1, pages 7.
Crossref
Xishan Lu, Haixia Xiao, Shihua Li, Xuefei Pang, Jian Song, Sheng Liu, Huijun Cheng, Yan Li, Xiangxi Wang, Chaobin Huang, Tianling Guo, Jan ter Meulen, Stephane Daffis, Jinghua Yan, Lianpan Dai, Zihe Rao, Hans-Dieter Klenk, Jianxun Qi, Yi Shi & George F. Gao. (2019) Double Lock of a Human Neutralizing and Protective Monoclonal Antibody Targeting the Yellow Fever Virus Envelope. Cell Reports 26:2, pages 438-446.e5.
Crossref
Cécile Chalouni & Sophia Doll. (2018) Fate of Antibody-Drug Conjugates in Cancer Cells. Journal of Experimental & Clinical Cancer Research 37:1.
Crossref
Mark Barok, Maija Puhka, Gyorgy Vereb, Janos Szollosi, Jorma Isola & Heikki Joensuu. (2018) Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. BMC Cancer 18:1.
Crossref
Dylan M. Glatt, Denis R. Beckford Vera, Shamit S. Prabhu, Russell J. Mumper, J. Christopher Luft, S. Rahima Benhabbour & Matthew C. Parrott. (2018) Synthesis and Characterization of Cetuximab–Docetaxel and Panitumumab–Docetaxel Antibody–Drug Conjugates for EGFR-Overexpressing Cancer Therapy. Molecular Pharmaceutics 15:11, pages 5089-5102.
Crossref
Ina Hellmann, Lorenz Waldmeier, Marie-Christine Bannwarth-Escher, Kseniya Maslova, Fabian I. Wolter, Ulf Grawunder & Roger R. Beerli. (2018) Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells. Frontiers in Immunology 9.
Crossref
Daniel Y. Lee, Kwang Suk Lim, Gabriel M. Valencia, Minjin Jung, David A. Bull & Young‐Wook Won. (2018) One‐Step Method for Instant Generation of Advanced Allogeneic NK Cells. Advanced Science 5:11.
Crossref
Lei Wang, Quanren Wang, Mingzhao Gao, Li Fu, Yun Li, Haitian Quan & Liguang Lou. (2018) STAT 3 activation confers trastuzumab‐emtansine (T‐ DM 1) resistance in HER 2‐positive breast cancer . Cancer Science 109:10, pages 3305-3315.
Crossref
Deboprosad Mondal, Jacob Ford & Kevin G. Pinney. (2018) Improved Methodology for the Synthesis of a Cathepsin B Cleavable Dipeptide Linker, Widely Used in Antibody-Drug Conjugate Research. Tetrahedron Letters 59:40, pages 3594-3599.
Crossref
Sophie Gong, Yuan Li, Wenji Su, Yu Ding, Jiaqi Lu, Kelly Dong, Steve Hood, Wandong Zhang & Georg C. Terstappen. (2018) Quantitative Algorithm-Based Paired Imaging Measurement for Antibody-Triggered Endocytosis in Cultured Cells. SLAS Discovery 23:8, pages 832-841.
Crossref
Zhuanglin Li, Mingxue Wang, Xuejing Yao, Huanzhao Li, Shenjun Li, Lina Liu, Deling Yu, Xue Li, Jianmin Fang & Changjiang Huang. (2018) Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment. International Immunopharmacology 62, pages 299-308.
Crossref
Hadi Nasiri, Zahra Valedkarimi, Leili Aghebati‐Maleki & Jafar Majidi. (2018) Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy. Journal of Cellular Physiology 233:9, pages 6441-6457.
Crossref
Byoung-Chul Lee, Cecile Chalouni, Sophia Doll, Sam C. Nalle, Martine Darwish, Siao Ping Tsai, Katherine R. Kozak, Geoffrey Del-Rosario, Shang-Fan Yu, Hans Erickson & Richard Vandlen. (2018) FRET Reagent Reveals the Intracellular Processing of Peptide-Linked Antibody–Drug Conjugates. Bioconjugate Chemistry 29:7, pages 2468-2477.
Crossref
Kenneth R. Durbin, Colin Phipps & Xiaoli Liao. (2018) Mechanistic Modeling of Antibody–Drug Conjugate Internalization at the Cellular Level Reveals Inefficient Processing Steps. Molecular Cancer Therapeutics 17:6, pages 1341-1351.
Crossref
Claudia Martínez-García, Yolanda Medina-Flores, José Manuel de la Rosa-Vázquez, Eva Elda Soriano-Pérez, Juan Ramón Villalobos-Hernández & Eva Ramón-Gallegos. (2018) Theranostic-PDT with the antibody anti isoform 4 SOD mitocondrial labeled with PpIX in the lung cancer cell line A-549. Photodiagnosis and Photodynamic Therapy 22, pages 197-204.
Crossref
Vera Luginbuehl, Nicolas Meier, Karin Kovar & Jack Rohrer. (2018) Intracellular drug delivery: Potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy. Biotechnology Advances 36:3, pages 613-623.
Crossref
Chad J. Pickens, Stephanie N. Johnson, Melissa M. Pressnall, Martin A. Leon & Cory J. Berkland. (2017) Practical Considerations, Challenges, and Limitations of Bioconjugation via Azide–Alkyne Cycloaddition. Bioconjugate Chemistry 29:3, pages 686-701.
Crossref
Yuan-Chiang Chung, Ching-Ming Chang, Wan-Chen Wei, Ting-Wei Chang, King-Jen Chang & Wei-Ting Chao. (2018) Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells. Scientific Reports 8:1.
Crossref
Weixian Zhou, Feifei Xu, Danni Li & Yun Chen. (2018) Improved Detection of HER2 by a Quasi-Targeted Proteomics Approach Using Aptamer–Peptide Probe and Liquid Chromatography–Tandem Mass Spectrometry. Clinical Chemistry 64:3, pages 526-535.
Crossref
Rong Wang, Liang Li, Shenghua Zhang, Yi Li, Xiaofei Wang, Qingfang Miao & Yongsu Zhen. (2018) A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30 + lymphomas . Molecular Oncology 12:3, pages 339-355.
Crossref
Jiunn H. Lin, Yue Guo & Weirong Wang. (2018) Challenges of Antibody Drug Conjugates in Cancer Therapy: Current Understanding of Mechanisms and Future Strategies. Current Pharmacology Reports 4:1, pages 10-26.
Crossref
Ajay Gogia, Jagdish Nigade, Chirag Desai, Babu K Govind, Chetan Deshmukh & Binay Swarup. (2021) Trastuzumab Emtansine: Antibody-drug Conjugate in Treatment of Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer. Indian Journal of Medical and Paediatric Oncology 39:01, pages 79-87.
Crossref
Frank Comer, Changshou Gao & Steve Coats. 2018. Innovations for Next-Generation Antibody-Drug Conjugates. Innovations for Next-Generation Antibody-Drug Conjugates 267 280 .
Penelope M. Drake & David Rabuka. (2017) Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends. BioDrugs 31:6, pages 521-531.
Crossref
Aiko Nagayama, Leif W. Ellisen, Bruce Chabner & Aditya Bardia. (2017) Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. Targeted Oncology 12:6, pages 719-739.
Crossref
Paul Malik, Colin Phipps, Andrea Edginton & Jonathan Blay. (2017) Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. Pharmaceutical Research 34:12, pages 2579-2595.
Crossref
Jie Yang, Ji-Feng Sun, Ting-Ting Wang, Xiao-Hong Guo, Jun-Xia Wei, Lin-Tao Jia & An-Gang Yang. (2017) Targeted inhibition of hantavirus replication and intracranial pathogenesis by a chimeric protein-delivered siRNA. Antiviral Research 147, pages 107-115.
Crossref
Philip W. Howard. 2017. Protein Therapeutics. Protein Therapeutics 271 309 .
Kenneth R. Durbin, M. Shannon Nottoli, Nathaniel D. Catron, Nicole Richwine & Gary J. Jenkins. (2017) High-Throughput, Multispecies, Parallelized Plasma Stability Assay for the Determination and Characterization of Antibody–Drug Conjugate Aggregation and Drug Release. ACS Omega 2:8, pages 4207-4215.
Crossref
Łukasz Opaliński, Aleksandra Sokołowska-Wędzina, Martyna Szczepara, Małgorzata Zakrzewska & Jacek Otlewski. (2017) Antibody-induced dimerization of FGFR1 promotes receptor endocytosis independently of its kinase activity. Scientific Reports 7:1.
Crossref
Hao Chen, Zongtao Lin, Kinsie Arnst, Duane Miller & Wei Li. (2017) Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Molecules 22:8, pages 1281.
Crossref
Jae Wook Kim. (2017) Antibody-Drug Conjugates in Head and Neck Cancer. Korean Journal of Otorhinolaryngology-Head and Neck Surgery 60:7, pages 331-335.
Crossref
Christoffer Fagernæs Nielsen, Sander Maarten van Putten, Ida Katrine Lund, Maria Carlsén Melander, Kirstine Sandal Nørregaard, Henrik Jessen Jürgensen, Kristian Reckzeh, Kristine Rothaus Christensen, Signe Ziir Ingvarsen, Henrik Gårdsvoll, Kamilla Ellermann Jensen, Petra Hamerlik, Lars Henning Engelholm & Niels Behrendt. (2017) The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers. Oncotarget 8:27, pages 44605-44624.
Crossref
Michaela L. McNiff & Jennifer S. Chadwick. (2017) Metal-bound claMP Tag inhibits proteolytic cleavage. Protein Engineering, Design and Selection 30:6, pages 467-475.
Crossref
Juozas Baltusnikas, Andrej Fokin, Johannes Winkler & Julius Liobikas. (2017) Long-term regulation of gene expression in muscle cells by systemically delivered siRNA. Journal of Controlled Release 256, pages 101-113.
Crossref
Marjorie De Schryver, Annelies Leemans, Isabel Pintelon, Davie Cappoen, Louis Maes, Guy Caljon, Paul Cos & Peter L. Delputte. (2017) Comparative analysis of the internalization of the macrophage receptor sialoadhesin in human and mouse primary macrophages and cell lines. Immunobiology 222:6, pages 797-806.
Crossref
Gennaro Riccio, Ana R. Da Fonseca-Ricardo, Margherita Passariello, Philip Cunnah, Nico Mertens & Claudia De Lorenzo. (2017) Superior Suppression of ErbB2-positive Tumor Cells by a Novel Human Triparatopic Tribody. Journal of Immunotherapy 40:4, pages 117-128.
Crossref
Rachel M. DeVay, Kathy Delaria, Guoyun Zhu, Charles Holz, Davide Foletti, Janette Sutton, Gary Bolton, Russell Dushin, Christine Bee, Jaume Pons, Arvind Rajpal, Hong Liang, David Shelton, Shu-Hui Liu & Pavel Strop. (2017) Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates. Bioconjugate Chemistry 28:4, pages 1102-1114.
Crossref
Julian Andreev, Nithya Thambi, Andres E. Perez Bay, Frank Delfino, Joel Martin, Marcus P. Kelly, Jessica R. Kirshner, Ashique Rafique, Arthur Kunz, Thomas Nittoli, Douglas MacDonald, Christopher Daly, William Olson & Gavin Thurston. (2017) Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. Molecular Cancer Therapeutics 16:4, pages 681-693.
Crossref
Yu-Jie Wang, Yu-Yan Li, Xiao-Yu Liu, Xiao-Ling Lu, Xin Cao & Bing-Hua Jiao. (2017) Marine Antibody–Drug Conjugates: Design Strategies and Research Progress. Marine Drugs 15:1, pages 18.
Crossref
Dirk Theile, Gal Lenz, Jamil A. Momand & Susan E. Kane. 2017. Resistance to Targeted Therapies in Breast Cancer. Resistance to Targeted Therapies in Breast Cancer 35 88 .
Guillaume Jacquot, Pascaline Lécorché, Jean-Daniel Malcor, Mathieu Laurencin, Maria Smirnova, Karine Varini, Cédric Malicet, Fanny Gassiot, Karima Abouzid, Aude Faucon, Marion David, Nicolas Gaudin, Maxime Masse, Géraldine Ferracci, Vincent Dive, Salvatore Cisternino & Michel Khrestchatisky. (2016) Optimization and in Vivo Validation of Peptide Vectors Targeting the LDL Receptor . Molecular Pharmaceutics 13:12, pages 4094-4105.
Crossref
Riley Ennis & Sourav Sinha. 2016. Antibody‐Drug Conjugates. Antibody‐Drug Conjugates 85 103 .
Jay Harper & Robert Hollingsworth. 2016. Antibody‐Drug Conjugates. Antibody‐Drug Conjugates 33 58 .
Carolin Sellmann, Achim Doerner, Christine Knuehl, Nicolas Rasche, Vanita Sood, Simon Krah, Laura Rhiel, Annika Messemer, John Wesolowski, Mark Schuette, Stefan Becker, Lars Toleikis, Harald Kolmar & Bjoern Hock. (2016) Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates. Journal of Biological Chemistry 291:48, pages 25106-25119.
Crossref
Rémy Gébleux & Giulio Casi. (2016) Antibody-drug conjugates: Current status and future perspectives. Pharmacology & Therapeutics 167, pages 48-59.
Crossref
Ji-Sun Kim, Dong-Ki Choi, Ju-Yeon Shin, Seung-Min Shin, Seong-Wook Park, Hyun-Soo Cho & Yong-Sung Kim. (2016) Endosomal acidic pH-induced conformational changes of a cytosol-penetrating antibody mediate endosomal escape. Journal of Controlled Release 235, pages 165-175.
Crossref
Adam Parslow, Sagun Parakh, Fook-Thean Lee, Hui Gan & Andrew Scott. (2016) Antibody–Drug Conjugates for Cancer Therapy. Biomedicines 4:3, pages 14.
Crossref
Yuan Lu, Yuan Wang, Mi Zhang, Li Liu, Fakai Li, Jian Zhang, Mingxiang Ye, Hu Zhao, Jing Zhao, Bo Yan, Angang Yang, Rui Zhang, Xia Li & Xinling Ren. (2016) HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth. Oncotarget 7:17, pages 23594-23607.
Crossref
Nidhi Nath, Becky Godat, Chad Zimprich, Stephen J. Dwight, Cesear Corona, Mark McDougall & Marjeta Urh. (2016) Homogeneous plate based antibody internalization assay using pH sensor fluorescent dye. Journal of Immunological Methods 431, pages 11-21.
Crossref
Srikumar M. Raja, Swapnil S. Desale, Bhopal Mohapatra, Haitao Luan, Kruti Soni, Jinjin Zhang, Matthew A. Storck, Dan Feng, Timothy A. Bielecki, Vimla Band, Samuel M. Cohen, Tatiana K. Bronich & Hamid Band. (2016) Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. Oncotarget 7:9, pages 10522-10535.
Crossref
Yaghoub Safdari, Vahideh Ahmadzadeh, Masoumeh Khalili, Hossein Zarei Jaliani, Vahid Zarei & Vahid Erfani-Moghadam. (2016) Use of Single-Chain Antibody Derivatives for Targeted Drug Delivery. Molecular Medicine 22:1, pages 258-270.
Crossref
Anupam Bandyopadhyay, Samantha Cambray & Jianmin Gao. (2016) Fast and selective labeling of N-terminal cysteines at neutral pH via thiazolidino boronate formation. Chemical Science 7:7, pages 4589-4593.
Crossref
Fei Cao, Qian Yao, Tieshan Yang, Zhao Zhang, Yu Han, Jinchao Feng & Xiu-Hong Wang. (2016) Marriage of antibody–drug conjugate with gold nanorods to achieve multi-modal ablation of breast cancer cells and enhanced photoacoustic performance. RSC Advances 6:52, pages 46594-46606.
Crossref
Chetan Rathi & Bernd Meibohm. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 16 .
Norbert SewaldMichael A Firer & Galia Luboshits. 2015. Optimizing Antibody-Drug Conjugates for Targeted Delivery of Therapeutics. Optimizing Antibody-Drug Conjugates for Targeted Delivery of Therapeutics 106 118 .
Norbert SewaldJay Harper & Adeela Kamal. 2015. Optimizing Antibody-Drug Conjugates for Targeted Delivery of Therapeutics. Optimizing Antibody-Drug Conjugates for Targeted Delivery of Therapeutics 74 88 .
Norbert SewaldNathan Higginson-Scott & Michael Ritchie. 2015. Optimizing Antibody-Drug Conjugates for Targeted Delivery of Therapeutics. Optimizing Antibody-Drug Conjugates for Targeted Delivery of Therapeutics 90 104 .
Ji-sun Kim, Dong-Ki Choi, Seong-wook Park, Seung-Min Shin, Jeomil Bae, Dong-Myung Kim, Tae Hyeon Yoo & Yong-Sung Kim. (2015) Quantitative assessment of cellular uptake and cytosolic access of antibody in living cells by an enhanced split GFP complementation assay. Biochemical and Biophysical Research Communications 467:4, pages 771-777.
Crossref
Shi Xu. (2015) Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates. Pharmaceutical Research 32:11, pages 3577-3583.
Crossref
Satish K. Singh, Donna L. Luisi & Roger H. Pak. (2015) Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability. Pharmaceutical Research 32:11, pages 3541-3571.
Crossref
Nareshkumar Jain, Sean W. Smith, Sanjeevani Ghone & Bruce Tomczuk. (2015) Current ADC Linker Chemistry. Pharmaceutical Research 32:11, pages 3526-3540.
Crossref
Yan Li, Peter Corbett Liu, Yang Shen, Marshall D. Snavely & Kaori Hiraga. (2015) A Cell-Based Internalization and Degradation Assay with an Activatable Fluorescence–Quencher Probe as a Tool for Functional Antibody Screening. SLAS Discovery 20:7, pages 869-875.
Crossref
Christina PetersStuart Brown. (2015) Antibody–drug conjugates as novel anti-cancer chemotherapeutics. Bioscience Reports 35:4.
Crossref
Yuan-Chiang Chung, Jang-Fang Kuo, Wan-Chen Wei, King-Jen Chang & Wei-Ting Chao. (2015) Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). PLOS ONE 10:7, pages e0133072.
Crossref
Hitesh Kulhari, Deep Pooja, Sri V. K. Rompicharla, Ramakrishna Sistla & David J. Adams. (2015) Biomedical Applications of Trastuzumab: As a Therapeutic Agent and a Targeting Ligand. Medicinal Research Reviews 35:4, pages 849-876.
Crossref
Tomas Baldassarre, Kathleen Watt, Peter Truesdell, Jalna Meens, Mark M. Schneider, Sandip K. Sengupta & Andrew W. Craig. (2015) Endophilin A2 Promotes TNBC Cell Invasion and Tumor Metastasis. Molecular Cancer Research 13:6, pages 1044-1055.
Crossref
A. N. Gargalionis, M. V. Karamouzis, C. Adamopoulos & A. G. Papavassiliou. (2015) Protein trafficking in colorectal carcinogenesis--targeting and bypassing resistance to currently applied treatments. Carcinogenesis 36:6, pages 607-615.
Crossref
LeeRon Shefet-Carasso & Itai Benhar. (2015) Antibody-targeted drugs and drug resistance—Challenges and solutions. Drug Resistance Updates 18, pages 36-46.
Crossref
Inna Vainshtein, Lorin K. Roskos, Jackie Cheng, Matthew A. Sleeman, Bing Wang & Meina Liang. (2014) Quantitative Measurement of the Target-Mediated Internalization Kinetics of Biopharmaceuticals. Pharmaceutical Research 32:1, pages 286-299.
Crossref
Heidi L. Perez, Pina M. Cardarelli, Shrikant Deshpande, Sanjeev Gangwar, Gretchen M. Schroeder, Gregory D. Vite & Robert M. Borzilleri. (2014) Antibody–drug conjugates: current status and future directions. Drug Discovery Today 19:7, pages 869-881.
Crossref
Sarah M. Cheal, Blesida Punzalan, Michael G. Doran, Michael J. Evans, Joseph R. Osborne, Jason S. Lewis, Pat Zanzonico & Steven M. Larson. (2014) Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 41:5, pages 985-994.
Crossref
Mark Barok, Heikki Joensuu & Jorma Isola. (2014) Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Research 16:2.
Crossref
Gladys S. Ingle & Suzie J. Scales. (2014) DropArray™, a Wall-Less 96-Well Plate for Uptake and Immunofluorescence Microscopy, Confirms CD22 Recycles. Traffic 15:3, pages 255-272.
Crossref
Yang Feng, Zhongyu Zhu, Weizao Chen, Ponraj Prabakaran, Kedan Lin & Dimiter Dimitrov. (2014) Conjugates of Small Molecule Drugs with Antibodies and Other Proteins. Biomedicines 2:1, pages 1-13.
Crossref
Rogério S. Gaspar, Helena F. Florindo, Liana C. Silva, Mafalda A. Videira, M. Luísa Corvo, Bárbara F. Martins & Beatriz Silva-Lima. 2014. Nano-Oncologicals. Nano-Oncologicals 425 452 .
Dhaval K ShahFrank Barletta, Alison Betts & Steven Hansel. (2013) Key bioanalytical measurements for antibody–drug conjugate development: PK/PD modelers’ perspective. Bioanalysis 5:9, pages 989-992.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.